Hostname: page-component-7c8c6479df-94d59 Total loading time: 0 Render date: 2024-03-29T07:53:34.400Z Has data issue: false hasContentIssue false

Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom

Published online by Cambridge University Press:  06 June 2006

N. L. GODDARD
Affiliation:
Health Protection Agency Centre for Infections, London, UK
M. C. COOKE
Affiliation:
Health Protection Agency Centre for Infections, London, UK
R. K. GUPTA
Affiliation:
Health Protection Agency Centre for Infections, London, UK
J. S. NGUYEN-VAN-TAM
Affiliation:
Health Protection Agency Centre for Infections, London, UK
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Respiratory syncytial virus (RSV) infection produces more severe disease and increased hospitalization rates in high-risk babies. The monoclonal antibody palivizumab offers protection against complications, and the first of five monthly doses should be administered before the onset of community RSV activity. However, the required real-time prediction of this onset is problematic. We attempted to identify seasonal RSV patterns by retrospectively examining 10 years of laboratory reports for RSV and clinical episode reports for certain respiratory presentations in both primary and secondary care. Analysis of hospital laboratory reports, incidence of acute bronchitis in primary care, and hospital admissions for acute bronchitis and bronchiolitis in young children revealed a consistent increase in RSV activity during week 43 each year. Promptly commencing prophylaxis during the second week of each October (week 42) would precede the onset of the RSV season in the United Kingdom, and provide coverage until its decline in mid-March.

Type
Short Report
Copyright
© 2006 Cambridge University Press